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downregulation by oestrogen might be a way to effec-
tively reduce A  burden via reduced   -secretase cleavage 
activity  [1] . This is in line with another recent paper 
showing that in an early-onset AD transgenic mouse 
model expressing double mutant APP (Swedish: K67ON/
M671L; Indiana: V717F) undergoing treatment with 17  -
oestradiol, significantly lower levels of APP processing 
via   -secretase are detectable  [3] . The question, however, 
is: does this new knowledge about the downregulation of 
BACE by oestrogen really help us much in understanding 
(and treating) APP processing in AD? Undoubtedly, the 
vast majority of cases of AD are sporadic (late onset) in 
origin. Patients suffering from sporadic AD possess a 
non-mutated (‘wild-type’) APP. Remarkably enough (and 
largely ignored in the literature), Hook’s group could 
show that the activity of the ‘established’   -secretase 
BACE1 for wild-type APP is extremely low, while other 
proteases (especially cathepsin B) are much more effec-
tive in cleaving APP at the wild-type secretase site  [5–7] . 
Thus, cathepsin B could be another putative   -secretase 
candidate (or even the dominating one) in sporadic AD 
 [5–7] . If so, we also have to ask about a possible effect of 
oestrogen treatment on cathepsin B. Unfortunately, we 
are not aware of any data about oestrogen-induced chang-
es in brain cathepsin B activity or expression, but find-
 The purpose of this short commentary is to add some 
thoughts on a particular aspect of the very interesting ar-
ticle by Dr. Csöregh Nord et al.  [1] which has recently ap-
peared in  Neurodegenerative Diseases. 
 Postmenopausal oestrogen depletion is a well-known 
risk factor for Alzheimer’s disease (AD). Previous studies 
suggest that oestrogen negatively regulates the level of 
amyloid   (A  ) in the brain, but the molecular mecha-
nism is largely unknown. Quite recently, the A  -degrad-
ing enzymes, insulin-degrading enzyme  [2, 3] and nepri-
lysin  [4] , have been identified to be upregulated by oes-
trogen, which in part might explain the beneficial effects 
of oestrogen in AD  [2] . Csöregh Nord et al.  [1] have now 
convincingly shown that oestrogen is involved in the reg-
ulation of gene expression of the putative   - and   -secre-
tases TACE (tumour-necrosis-factor-  -converting en-
zyme) and presenilin. Even more importantly, BACE
[  -site of amyloid-precursor-protein (APP)-cleaving en-
zyme] protein expression (but not the gene coding for 
BACE) was demonstrated to be significantly downregu-
lated by oestrogen treatment in mixed human neuronal/
glial cell cultures. Csöregh Nord et al.  [1] conclude that 
oestrogen may affect APP processing directly by regulat-
ing the expression of the involved enzymes. In particular, 
since BACE is regarded the principal   -secretase, its 
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ings from non-neural tissues indicate that cathepsin B 
becomes upregulated under the influence of the hormone 
 [8, 9] . Hence, it would be very interesting to look for the 
oestrogen-dependent expression of the alternative (or ad-
ditional)   -secretase cathepsin B in the neuronal cell sys-
tem used by Csöregh Nord et al.  [1] in their study. If brain-
associated cathepsin B is really upregulated under the 
 influence of oestrogen, whereas BACE expression is 
downregulated, an elevated (and not a reduced)   -secre-
tase activity might result in cases of sporadic AD. How-
ever, due to the effects which oestrogen has on   - and 
  -secretases  [1] as well as on A  -degrading enzymes  [2–
4] , the net effect of the hormone on amyloid burden would 
probably still be a reduction, which would fit with obser-
vations previously made  [1, 3] . 
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